Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2012 |
| Автори: | , , , , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2012
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/139877 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862633708313378816 |
|---|---|
| author | Naumnik, W. Naumnik, B. Niewiarowska, K. Ossolinska, M. Chyczewska, E. |
| author_facet | Naumnik, W. Naumnik, B. Niewiarowska, K. Ossolinska, M. Chyczewska, E. |
| citation_txt | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies.
|
| first_indexed | 2025-11-30T15:30:01Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-139877 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-11-30T15:30:01Z |
| publishDate | 2012 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Naumnik, W. Naumnik, B. Niewiarowska, K. Ossolinska, M. Chyczewska, E. 2018-06-21T12:58:45Z 2018-06-21T12:58:45Z 2012 Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/139877 There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies. We are indebted to Robert Mroz for his help
 with the ELISA equipment. This work was granted
 by Polish Ministry of Science and Higher Education
 (NN 401 230134; 2301/B/P01/2008/34). en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Original contributions Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Article published earlier |
| spellingShingle | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Naumnik, W. Naumnik, B. Niewiarowska, K. Ossolinska, M. Chyczewska, E. Original contributions |
| title | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? |
| title_full | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? |
| title_fullStr | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? |
| title_full_unstemmed | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? |
| title_short | Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? |
| title_sort | novel cytokines: il-27, il-29, il-31 and il-33. can they be useful in clinical practice at the time diagnosis of lung cancer? |
| topic | Original contributions |
| topic_facet | Original contributions |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/139877 |
| work_keys_str_mv | AT naumnikw novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer AT naumnikb novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer AT niewiarowskak novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer AT ossolinskam novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer AT chyczewskae novelcytokinesil27il29il31andil33cantheybeusefulinclinicalpracticeatthetimediagnosisoflungcancer |